
Caliber Therapeutics develops and commercializes balloon-based drug delivery products for atherosclerotic diseases.
Caliber Therapeutics, founded to address the needs of patients with atherosclerotic diseases, focuses on developing and commercializing minimally-invasive balloon-based drug delivery products. Their core mission is to provide innovative solutions that enable controlled and targeted drug delivery, thereby reducing thrombosis risk and the need for permanent implants. The company's flagship product, the Targeted Angioplasty Drug Delivery balloon, exemplifies this mission by offering a stent-free platform for anti-restenotic drugs.
Notable affiliated people include key figures in biomedical innovation and strategic partnerships with leading medical device companies. Caliber Therapeutics has achieved significant milestones in advancing their therapeutic pipeline and forming risk-reward sharing partnerships to accelerate global commercialization. Their impact is marked by the potential to transform the treatment landscape for atherosclerotic diseases, improving patient outcomes through innovative drug delivery solutions.

Talima Therapeutics
talima.com

Stealth Therapeutics

Mechano-Therapeutics

Bioabsorbable Therapeutics

Underdog Pharmaceuticals
cyclaritytx.com

Theracos
theracos.com

Theradaptive
theradaptive.com

Thrombolex
thrombolex.com

Intact Therapeutics

Advanced Catheter Therapies
acatheter.com

Edulis Therapeutics
edulis.xyz

Anthos Therapeutics

CeleCor Therapeutics
celecor.com

Embolx
embolx.com

Concentric Analgesics
Companies similar to Orchestra BioMed include Talima Therapeutics, Stealth Therapeutics, Mechano-Therapeutics and Bioabsorbable Therapeutics.
Orchestra BioMed was founded in 2005.
Orchestra BioMed's headquarters is located in New Hope, PA, US.
Orchestra BioMed's most recent funding round was for $12M (USD) in June 2017.
As of Jun 13, 2017, Orchestra BioMed has raised a total of $12M (USD).